Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.

Alnylam Pharmaceuticals, Inc. ALNY announced that the European Commission (EC) has approved a label expansion of its RNAi therapeutic Amvuttra.The EC has now approved Amvuttra for the treatment of ...

Alnylam Pharmaceuticals (Nasdaq: ALNY) has won European Commission approval for Amvuttra (vutrisiran) to treat transthyretin ...

The fact that multiple Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) insiders offloaded a considerable amount of ...

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the polyneuropathy manifestations of ATTR amyloidosis and hereditary transthyretin ...

See the latest Alnylam Pharmaceuticals Inc stock price (ALNY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Alnylam Pharmaceuticals ALNY +1.01% Get Free Report is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish ...

For payers, claims for rare disease treatments used to be uncommon. Not anymore, thanks to an increasing number of new, ...

Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer. The company said Wednesday that Garg will help oversee an integrated R&D organization to ...

Review the current Alnylam Pharmaceuticals Inc (ALNY:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if ALNY is the best investment for you.